BSD Medical, a manufacturer of services systems to treat cancer using heat therapy, will start Phase III pancreatic cancer study.

The randomized, multicenter study will use the BSD-2000 Hyperthermia System to deliver hyperthermia.

The study will compare hyperthermia with chemotherapy (gemcitabine plus cisplatin) to chemotherapy (gemcitabine) alone.

BSD said patients will be randomized following standard surgical resection of the tumor, and the enrollment is scheduled from 1 April 2012.